Gynecologic Oncology
Clinical discussions on gynecologic malignancies, surgical approaches, and multimodal treatment strategies.
Recent Discussions
Does the path length of vaginal cuff cylinder brachytherapy treatment as adjuvant therapy for endometrial cancer vary based on histology (serous, etc)?
There was some thought that treatment of high risk histologies, positive LVI, or high Grade required a longer vaginal length be treated. Including 2/3 or full length. That is largely unsupported by high-quality data and would increase distal vagina toxicity in this population. Our clinic treats uppe...
If a patient meets criteria for extrafascial hysterectomy for early-stage cervical cancer, how do you determine your surgical approach (abdominal vs laparoscopic)?
For FIGO 1A1-1A2 (i.e., microinvasion which means no visible lesion) - I would perform a vaginal hysterectomy with bilateral salpingectomy (IA1) or robotic hysterectomy with bilateral salpingectomy-nodes (IA2); for FIGO 1B1 with no visible lesion (eg., post-conization), I would perform a robotic cys...
How would you approach a patient who is unable to undergo the recommended ophthalmologic examinations during treatment with mirvetuximab soravtansine?
Until more data are available regarding the ocular safety and reviewed by the agency, I follow the recommendations. I feel there is a decent chance real-world experience may change this but officially I follow the recommendations as stated. Having said this, the testing recommended (“Conduct an opht...
Would you ever consider pelvic exenteration followed by SBRT for a patient with recurrent cervical cancer (s/p chemoRT) who has disease only in the central pelvis and in a single hilar lymph node?
I think this is a tough question. The short of it would be that I would be very cautious with exent candidacy with extra-pelvic disease. The surgical morbidity and limited ability to get additional therapy are a reality. Scenarios where I might consider would be a long duration of time off therapy. ...
How do you manage a cervical cancer patient on anti-coagulation for pulmonary embolism requiring interstitial brachytherapy boost?
Have done with IVC filter and switch to heparin days prior to the procedure so that can hold anti coagulant for the procedure and epidural placement for analgesia.
How would you palliate a large, symptomatic vaginal melanoma recurrence with limited small pelvic lymph node metastases?
Palliation. Treat problems that are symptomatic. No expensive systemic work up. Pall RT to the pelvis if it’s symptomatic. 30 Gy/10 fractions, 25 Gy/5 fractions, or 20 Gy/2 fractions with a 1 week inter-fraction interval. Apologize for the lengthy response.
Between KEYNOTE A-18 and INTERLACE, for which patients would you recommend using one protocol over another?
We currently favor A-18 for stage III disease (clinical or node-positive). A-18 had a more modern RT technique both for EBRT and brachytherapy while in INTERLACE, 60% had a prescription to point A for brachytherapy. In comparison with the EMBRACE 3D brachytherapy series, pelvic recurrence rate seems...
With vaginal cuff brachytherapy, do you treat to the surface or a depth and why?
We prescribe to the surface of the vagina but also attend to the dose at depth. For patients receiving only vaginal cuff irradiation we use a prescription of 6 Gy VSD x 5 qod. Although this is a modest dose, it appears to be very effective in preventing vaginal recurrences, even in high-risk cases. ...
How do you logistically incorporate a "scope and score" of a patient with newly diagnosed advanced ovarian cancer into a busy OR schedule?
This can definitely be tricky. In my practice, I typically scope and score the same day as I plan to do their debulking surgery, booking cases like this as the last case of the day. While I do have block time in the OR, it is hard to take a patient for scope and score to then return in a short inter...
Is there a role for definitive radiotherapy in patients with de-novo metastatic cervical cancer after achieving complete response with chemo-immunotherapy per KEYNOTE-826?
We don't know the true impact of local treatment or the durability of CR from chemo IO response. In situations like this, I have sometimes done brachy alone to treat the primary site for local control and prevent future symptomatology.